0
Pain Management in
Dementia: what’s new in
opioids?
Romayne Gallagher MD, CCFP
Division of Palliative Care
Providence Heal...
Objectives
Basics of pain in dementia
NOUG – is it useful for pain in dementia?
New opioids
New opioid formulations
Prevalence of pain in older adults
Prevalence of any kind of pain is stable
with increasing age
Scudds & Ostbye 2001, Thom...
Pain Homeostenosis
Diminshed ability to effectively respond to the
stress of persistent pain








Decreased cogn...
Cognitive Impairment (CI) & Pain
Management: Nursing Homes
Pain is documented less frequently for CI
residents, even with ...
Ability to self-report pain

Pain Self-Report and Cognitive
Impairment in Dementia Patients

Nonverbal

Cognitive impairme...
Undertreatment of Pain in Patients
With Advanced Dementia

Prospective cohort study of 59 cognitively
intact elderly patie...
Analgesic Prescribing in Hip Fracture
Patients with Advanced Dementia
Pre-op

Mg MSO4/Day

76% of cog. intact
patients rat...
Analgesic Prescribing For Dementia Patients
Following Hip Fracture Repair
As Needed

Standing

24%

76%

Morrison & Siu, J...
Assessment of Pain in Dementia:
Medical Problems - Previous and Current
Concurrent medical problems (esp. hepatic, renal)
...
Hierarchy of Data Sources

Most reliable

Resident report (if
possible)
Prior pain history
Painful diagnoses
Behavioral in...
Empirical Trials
Try pain medicine

Behaviours suggest it
could be pain

Behaviours decrease

It’s probably pain!

12
What do I need to know to
be a better prescriber in
older adults?
Maintaining drug levels in the
body
drug delivery
Maximum safe
concentration

Minimum effective
concentration
General factors affecting absorption, distribution &
elimination - Age
Absorption: Changes in drug absorption tend to be
c...
General factors affecting
absorption, distribution & elimination - Age
Hepatic metabolism: mass and blood flow decreases
w...
General factors affecting
absorption, distribution & elimination - Age
Reduction in hepatic metabolism
Presystemic (first-...
General factors affecting
absorption, distribution & elimination - Age
Reduction in renal clearance with age
The renal mas...
Opioid Induced Neurotoxicity
Definition


Neuroexcitability manifested by agitation, confusion,
myoclonus, hallucinations...
Opioids and Older Adults
Opioids have been associated with a
higher risk of fracture (so has chronic pain)
Opioids have be...
Delirium in Hip Fracture Patients
541 patients, no delirium at entry to study
16% of patients became delirious
Subjects ab...
What is new in opioids?
National Opioid Use Guidelines
New opioids available



tapentadol, tramadol
buprenorphine

New ...
National Opioid Use Guidelines
National opioid use group: mostly
regulators
Literature review by researchers who
derived r...
Opioid Guidelines
Generally very useful and worth following
http://nationalpaincentre.mcmaster.ca/opioid/

The bias is tow...
Opioid Guidelines
Opioid suggestions for frail older adults do
not make pharmacokinetic sense


Codeine and tramadol
Shor...
Opioid classes
Are all opioids the same?









Opioids bind to three opioid receptors with
differing effects
There...
Opioids of choice
in frail elderly and renal failure
Hydromorphone
Oxycodone
Fentanyl
Methadone

27
Equianalgesic conversion
Morphine
Tylenol #3
Codeine
Hydromorphone
Oxycodone
Methadone
variable ratio

10mg
2 tablets
60mg...
Equianalgesic conversion
Fentanyl is highly lipophilic
A 25mcg fentanyl patch = 100mg
morphine/day = 20 Tylenol #3 per day
Notes about the Fentanyl patch
Takes 12 hours for onset of analgesia
Need adequate subcutaneous tissue for
absorption
Take...
OxyNeo replaces OxyContin
Oxycodone in a new formulation
Turns to gel on contact with water



not injectable
can’t dela...
Targin
Oxycodone with core of naloxone
Lower incidence of constipation
Naloxone not absorbed from the gut – no
effect on a...
Tramadol
Tramadol available in Europe (30 years) and US (12
yrs)
Dual Action



Opioid agonist
Inhibits reuptake of Sero...
Tapentadol
Very similar to tramadol but new
Dual action – mu receptor agonist and
norepinephrine reuptake inhibitor
Short ...
Buprenorphine
Semi-synthetic derivative of
morphine alkaloid thebaine
Highly lipid-soluble
High affinity for the μ-opioid
...
Buprenorphine
Partial agonist of mu receptor
Requires metabolism to become analgesic
Ceiling effect – consider as a weak o...
The BuTrans® Patch
Transdermal delivery eliminates first-pass metabolism
Patch delivers very small amounts of buprenorphin...
Bu-Trans patch
Experience in other countries is good
Useful for moderate pain
Potential for use in residential care as
wou...
Incident Pain
Sufentanil for incident pain
Well absorbed through buccal, sublingual
and nasal mucosa






Onset is 5-10 minutes
Cl...
Intranasal application
Inexpensive
Reusable on same pt
New formulations of fentanyl
Abstral – fentanyl buccal tablets
Onsolis – fentanyl buccal film
More effective than sl or in...
Topical Opioids
Ischemic ulcers, pressure ulcers,
fungating tumors
Morphine 1% concentration in intra-site
gel
Methadone 1...
Methadone in older adults
Well tolerated and effective
Starting dose 1mg q12hr
Well absorbed orally and bucally
Titrate on...
Methadone in older adults
Many potential interactions but few are
clinically significant
Clinically significant:




Cl...
Titrating opioids
Increase dose by 15-20% each time if
symptom not controlled
Starting with long acting opioids?






...
Treating side effects
Docusate not useful
Senna helpful but can cause cramps
Lactulose works well but horrible taste
PEG 3...
Neuropathic Pain Adjuvants
Anticonvulsants not well tolerated in oldest
adults – ie gabapentin, pregabalin,
topiramate


...
Neuropathic Pain Adjuvants
TCAs have intolerable side effects


In a trial of TCA vs opioids for neuropathic pain both
we...
Pain and depression
Study of 524 older adults
Pain hinders recovery from depression
Mavandadi et al JAGS 2007

Disabling c...
Interventional pain management
Epidural steroid injections: for spinal
stenosis, facet joint, nerve compression
secondary ...
Take Home Messages
Older adults with chronic pain are not the
same as younger patients with pain
There is “pain homeosteno...
Take Home Messages
Minimize polypharmacy
Opioids are a safer choice in older adults
Opioids with no active metabolites are...
Questions? Cases?
Upcoming SlideShare
Loading in...5
×

Pain+management+in+dementia april 2012

736

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
736
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
23
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Pain+management+in+dementia april 2012"

  1. 1. Pain Management in Dementia: what’s new in opioids? Romayne Gallagher MD, CCFP Division of Palliative Care Providence Health Care
  2. 2. Objectives Basics of pain in dementia NOUG – is it useful for pain in dementia? New opioids New opioid formulations
  3. 3. Prevalence of pain in older adults Prevalence of any kind of pain is stable with increasing age Scudds & Ostbye 2001, Thomas et al 2004 Prevalence of persistent disabling pain increases with age Brattberg et al 1996, Mobily et al 1994
  4. 4. Pain Homeostenosis Diminshed ability to effectively respond to the stress of persistent pain        Decreased cognitive reserves Decreased opioid receptors, neurotransmitors Altered pharmacokinetics/pharmacodynamics Polypharmacy Medical comorbidity Social isolation, depression, loneliness Impairments in ADL  Karp et al. Brit. J. of Anesthesia 2008
  5. 5. Cognitive Impairment (CI) & Pain Management: Nursing Homes Pain is documented less frequently for CI residents, even with similar numbers of painful diagnoses as less impaired residents (Sengstaken & King, 1993) Less analgesic is prescribed/administered for CI residents, despite similar numbers of painful diagnoses (Horgas & Tsai, 1998) Only ¼ of demented residents who are identified as having pain receive any analgesic therapy (Scherder et al, 1999; Bernabei et al, 1998; Won et al, 1999) 5
  6. 6. Ability to self-report pain Pain Self-Report and Cognitive Impairment in Dementia Patients Nonverbal Cognitive impairment 6
  7. 7. Undertreatment of Pain in Patients With Advanced Dementia Prospective cohort study of 59 cognitively intact elderly patients with hip fracture and 38 patients with hip fracture and advanced dementia Daily rating of pain by cognitively intact patients Comparison of analgesic prescribing practices Morrison & Siu, JPSM, 2000 7
  8. 8. Analgesic Prescribing in Hip Fracture Patients with Advanced Dementia Pre-op Mg MSO4/Day 76% of cog. intact patients rated their average preoperative pain as moderate-severe 68% of cog. intact patients rated their average postoperative pain as moderate to severe Post-op 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 Cog Intact Dementia Morrison & Siu, JPSM, 2000 8
  9. 9. Analgesic Prescribing For Dementia Patients Following Hip Fracture Repair As Needed Standing 24% 76% Morrison & Siu, JPSM, 2000 9
  10. 10. Assessment of Pain in Dementia: Medical Problems - Previous and Current Concurrent medical problems (esp. hepatic, renal) Allergies Past painful conditions Past medical history    Hospitalizations Surgery Serious illness 10
  11. 11. Hierarchy of Data Sources Most reliable Resident report (if possible) Prior pain history Painful diagnoses Behavioral indicators Observer assessment Response to empirical therapy Least reliable 11
  12. 12. Empirical Trials Try pain medicine Behaviours suggest it could be pain Behaviours decrease It’s probably pain! 12
  13. 13. What do I need to know to be a better prescriber in older adults?
  14. 14. Maintaining drug levels in the body drug delivery Maximum safe concentration Minimum effective concentration
  15. 15. General factors affecting absorption, distribution & elimination - Age Absorption: Changes in drug absorption tend to be clinically inconsequential. Distribution: Lean mass to fat ratio can change with age resulting in higher concentrations of fat-soluble drugs Serum albumin decreases so in a patient with malnutrition, this may enhance drug effects because serum concentrations of unbound drug are increased.
  16. 16. General factors affecting absorption, distribution & elimination - Age Hepatic metabolism: mass and blood flow decreases which can affect hepatic drug elimination. The hepatic metabolism is reduced and clearance can fall by 30 to 40%. However, the rate of drug metabolism can vary greatly from person to person. The possibility of hepatotoxicity is generally enhanced in the elderly.
  17. 17. General factors affecting absorption, distribution & elimination - Age Reduction in hepatic metabolism Presystemic (first-pass) metabolism of some drugs given orally (eg, labetalol, propranolol, verapamil) is decreased, increasing their serum concentration and bioavailability. Many drugs produce active metabolites in clinically relevant concentrations. Examples are some benzodiazepines, amitriptyline and opioid analgesics such as morphine. The accumulation of active metabolites can cause toxicity in the elderly due to age-related decreases in renal clearance. Toxicity is likely to be severe in those with renal disease.
  18. 18. General factors affecting absorption, distribution & elimination - Age Reduction in renal clearance with age The renal mass and renal blood flow decreases significantly Renal physiological changes decrease renal drug elimination. Because renal function continues to decline, the dose of drugs given long-term needs to be reviewed periodically. Elderly people may also have a reduced rate of compliance Disease - Liver and renal disease reduces rate of elimination
  19. 19. Opioid Induced Neurotoxicity Definition  Neuroexcitability manifested by agitation, confusion, myoclonus, hallucinations and rarely seizures Predisposing Factors:        High opioid doses Prolonged opioid use Recent rapid dose escalation Dehydration Renal failure Advanced age – lack of cognitive reserve, pharmacokinetics changes Other psychoactive drugs *Daeninck PJ, Bruera E. Acta Anaesthesiol Scand. 1999
  20. 20. Opioids and Older Adults Opioids have been associated with a higher risk of fracture (so has chronic pain) Opioids have been associated with delirium - but so have many other medications Most of the studies do not differentiate between opioids or involve pain as a risk factor
  21. 21. Delirium in Hip Fracture Patients 541 patients, no delirium at entry to study 16% of patients became delirious Subjects able to self-report pain  Severe pain prior to delirium OR 9.0 p=0.01  Low doses of opioids (<10 mg of parenteral milligrams of mso4/day) OR 4.4 p=0.03   Received meperidine (NS) Increase in opioid dose after pain detected (NS) Subjects unable to self-report pain  Low doses of opioids (<10 mg of parenteral milligrams of mso4/day) OR 4.0 p=0.004  Received meperidine OR 3.4 p=.001 21 Morrison et al, J Gerontol Med Sci, 2003
  22. 22. What is new in opioids? National Opioid Use Guidelines New opioids available   tapentadol, tramadol buprenorphine New formulations of oxycodone & fentanyl
  23. 23. National Opioid Use Guidelines National opioid use group: mostly regulators Literature review by researchers who derived recommendations National Advisory Panel – Delphi Process Responses from NAP not made public
  24. 24. Opioid Guidelines Generally very useful and worth following http://nationalpaincentre.mcmaster.ca/opioid/ The bias is towards the prevention of opioid abuse and diversion – appropriate for about 10% of chronic pain population
  25. 25. Opioid Guidelines Opioid suggestions for frail older adults do not make pharmacokinetic sense  Codeine and tramadol Short-acting opioids Both must be metabolized to be active Codeine metabolized to morphine and active metabolites accumulate in renal failure q4hr opioids in residential care is nursing nightmare
  26. 26. Opioid classes Are all opioids the same?      Opioids bind to three opioid receptors with differing effects There are at least two distinct classes of opioids based on structure Methadone also targets NMDA receptors There are two pathways of metabolism for opioids Two opioids are lipophilic and the rest are more hydrophillic
  27. 27. Opioids of choice in frail elderly and renal failure Hydromorphone Oxycodone Fentanyl Methadone 27
  28. 28. Equianalgesic conversion Morphine Tylenol #3 Codeine Hydromorphone Oxycodone Methadone variable ratio 10mg 2 tablets 60mg 2mg 5-7.5mg 1mg (not q4hr)
  29. 29. Equianalgesic conversion Fentanyl is highly lipophilic A 25mcg fentanyl patch = 100mg morphine/day = 20 Tylenol #3 per day
  30. 30. Notes about the Fentanyl patch Takes 12 hours for onset of analgesia Need adequate subcutaneous tissue for absorption Takes 24 hours to reach maximum effect Change patch every 72 hours Dosage change after six days on patch Suitable for stable pain only
  31. 31. OxyNeo replaces OxyContin Oxycodone in a new formulation Turns to gel on contact with water   not injectable can’t delay swallowing Extremely crush resistant Special authority needed
  32. 32. Targin Oxycodone with core of naloxone Lower incidence of constipation Naloxone not absorbed from the gut – no effect on analgesia Comes in 10, 20, 40mg oxycodone size Naloxone core too large for 5mg SR size so will be phased out Not covered by Pharmacare
  33. 33. Tramadol Tramadol available in Europe (30 years) and US (12 yrs) Dual Action   Opioid agonist Inhibits reuptake of Serotonin and Norepinephrine Metabolism: like codeine requires metabolism to become active View as a weak opioid – ie for moderate pain Available dosage strengths (CR tramadol, q24h)    150, 200, 300 and 400 mg 150mg q24h is the usual adult starting dose for opioid naïve patients Not to exceed 400 mg total daily dose
  34. 34. Tapentadol Very similar to tramadol but new Dual action – mu receptor agonist and norepinephrine reuptake inhibitor Short acting formulation only May be more potent than tramadol Not covered by Pharmacare Needs a duplicate prescription pad
  35. 35. Buprenorphine Semi-synthetic derivative of morphine alkaloid thebaine Highly lipid-soluble High affinity for the μ-opioid receptor   Potent partial agonist action Thought to dissociate slowly from the receptor
  36. 36. Buprenorphine Partial agonist of mu receptor Requires metabolism to become analgesic Ceiling effect – consider as a weak opioid Slow onset, highly bound to receptor Highly lipophilic
  37. 37. The BuTrans® Patch Transdermal delivery eliminates first-pass metabolism Patch delivers very small amounts of buprenorphine  Low plasma concentrations: levels measured in picograms (one trillionth of a gram or 10-12 g) per milliliter Buprenorphine binds and dissociates from the mu-receptor slowly  May account for the prolonged duration of analgesia and, in part, for its limited physical dependence potential Patch provides steady delivery of buprenorphine for up to 7 days  Steady state concentrations achieved during the first application after day 3 Clinical significance has not been fully established. Purdue Pharma Canada. BuTrans® Product Monograph, February 2010.
  38. 38. Bu-Trans patch Experience in other countries is good Useful for moderate pain Potential for use in residential care as would reduce work load of administering pills Not covered by Pharmacare
  39. 39. Incident Pain
  40. 40. Sufentanil for incident pain Well absorbed through buccal, sublingual and nasal mucosa      Onset is 5-10 minutes Cleared in 30 minutes 12.5mcg- 25mcg starting dose Up to 100mcg per dose For sublingual use must be able to follow directions
  41. 41. Intranasal application Inexpensive Reusable on same pt
  42. 42. New formulations of fentanyl Abstral – fentanyl buccal tablets Onsolis – fentanyl buccal film More effective than sl or intranasal sufentanil   pH adjusted less chance of swallowing and inactivating medication Not covered by Pharmacare
  43. 43. Topical Opioids Ischemic ulcers, pressure ulcers, fungating tumors Morphine 1% concentration in intra-site gel Methadone 1% concentration in inert wound powder
  44. 44. Methadone in older adults Well tolerated and effective Starting dose 1mg q12hr Well absorbed orally and bucally Titrate once weekly only Use other short acting opioid for breakthrough pain while titrating methadone Use methadone for breakthrough dose bid-tid once on stable dose Gallagher Pain Med. 2009
  45. 45. Methadone in older adults Many potential interactions but few are clinically significant Clinically significant:    Clarithromycin, rifampin Carbamazepine, phenytoin Fluconazole, ketoconazole QTc prolongation in doses greater than 100-200mg per day
  46. 46. Titrating opioids Increase dose by 15-20% each time if symptom not controlled Starting with long acting opioids?    In residential care inadequate staff to do q4hr opioids Oxycodone SR 10mg = 3 Tylenol #3 Hydromorphone SR 3mg = 3 Tylenol #3 Methadone 1mg q12 hrs = 2 Tylenol #3 ½ 12mcg patch = 5 Tylenol #3
  47. 47. Treating side effects Docusate not useful Senna helpful but can cause cramps Lactulose works well but horrible taste PEG 3350 (Laxaday) works well and can be mixed with drink of choice
  48. 48. Neuropathic Pain Adjuvants Anticonvulsants not well tolerated in oldest adults – ie gabapentin, pregabalin, topiramate  32% withdrawal from study of pregabalin in neuropathic pain Dworkin et al Neurology 2003
  49. 49. Neuropathic Pain Adjuvants TCAs have intolerable side effects  In a trial of TCA vs opioids for neuropathic pain both were effective but patients preferred opioids (54%) to TCAs(30%) to placebo(10%) p=0.02 Raja et al Neurology 2003 SNRIs are likely the best option for older adults with neuropathic pain  Study of >80 years old found it safe and efficacious for depression Baca et al Int J Geriatr Psychiatry 2006
  50. 50. Pain and depression Study of 524 older adults Pain hinders recovery from depression Mavandadi et al JAGS 2007 Disabling chronic low back pain and depression were independent factors that increased the prevalence of each other Meyer et al Spine 2007 Anxiety is also a predictor of pain Feeney J. Anxiety Disord 2004
  51. 51. Interventional pain management Epidural steroid injections: for spinal stenosis, facet joint, nerve compression secondary to OA Vertebroplasty for lumbar compression fractures causing uncontrollable pain/disability
  52. 52. Take Home Messages Older adults with chronic pain are not the same as younger patients with pain There is “pain homeostenosis” (less ability to respond effectively to the stress of chronic pain) Older adults are more likely to loose function with chronic pain if there is a lack of timely intervention
  53. 53. Take Home Messages Minimize polypharmacy Opioids are a safer choice in older adults Opioids with no active metabolites are a better choice in older adults If patients with dementia and pain become drowsy with opioid try reducing neuroleptics Analgesic trials while monitoring behaviour Analgesic trials need to include opioids
  54. 54. Questions? Cases?
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×